Literature DB >> 31085049

New treatment for relapsed or refractory Hodgkin's lymphoma.

Elizabeth Gourd.   

Abstract

Entities:  

Year:  2019        PMID： 31085049     DOI： 10.1016/S1470-2045(19)30289-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Could Camrelizumab Plus Chemotherapy Improve Clinical Outcomes in Advanced Malignancy? A Systematic Review and Network Meta-Analysis.

Authors:  Chao Yang; Chang Xu; Xiang Li; Yaowen Zhang; Simeng Zhang; Tongyu Zhang; Yingshi Zhang
Journal:  Front Oncol       Date:  2021-08-09       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.